Changes in cognition through a combined memory and psychomotor training intervention in patients with Cancer Related Cognitive Impairment: a randomized controlled trial.

Changes in cognition through a combined memory and psychomotor training intervention in patients with Cancer Related Cognitive Impairment: a randomized controlled trial. - MPMI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00027361

Enrollment

170

Registered

2021-12-02

Start date

2023-12-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer related cognitive impairment

Interventions

Group 1: Intervention group: After recruitment, each participant will receive a baseline examination (T1) and follow-up examinations after 3 months (T2) and after 6 months (T3). After T1, a randomized

Haas, R., Golmert, C, & Kühn, C. 2014). All participants are given the opportunity to take advantage of a psycho-oncological consultation if needed. Group 2: Control group: After recruitment, each par

Eligibility

Sex/Gender

All

Age

18 Years to 79 Years

Inclusion criteria

Inclusion criteria: - curative tumor diagnosis (malignant Neoplasia) - after chemotherapy and/or radiotherapy and/or ongoing antibody therapy - age at least 18 years to 79 years - subjective cognitive impairment (FACT-COG <=55) - access to a device with internet access

Exclusion criteria

Exclusion criteria: - lack of German language skills and linguistic disorders - severe cognitive impairment such as dementia - brain tumors - immobile, bedridden and unstable resilient patients - patients with palliative therapy goals

Design outcomes

Primary

Measure	Time frame
The change in cognition via alertness (without signal tone) is examined with the test battery of attentional performance (TAP).Reaction time in milliseconds is measured at time points T1-T3 (T1: baseline; T2: after 3 months; T3: after 6 months).	—

Secondary

Measure	Time frame
-Cognition (objective): tests of attention performance via alertness (with signal), go/nogo, working memory; verbal learning and memory test; trail making test A and B. - Cognition (PRO): FACT-Cog. - Health-related quality of life (PRO): EORTC-QLQ-C30; - Cancer-related fatigue (PRO): EORTC-QLQ-FA12; - Depression (PRO): PHQ9; anxiety (PRO): GAD7. -Physical performance: 6-minute walking test. Confounders: sociodemographic data, medical data All parameters (except sociodemographic data: collected only at T1) will be collected at time points T1-T3 (T1: baseline examination; T2: after 3 months; T3: after 6 months).	—

Measure

Time frame

-Cognition (objective): tests of attention performance via alertness (with signal), go/nogo, working memory; verbal learning and memory test; trail making test A and B. - Cognition (PRO): FACT-Cog. - Health-related quality of life (PRO): EORTC-QLQ-C30; - Cancer-related fatigue (PRO): EORTC-QLQ-FA12; - Depression (PRO): PHQ9; anxiety (PRO): GAD7. -Physical performance: 6-minute walking test. Confounders: sociodemographic data, medical data All parameters (except sociodemographic data: collected only at T1) will be collected at time points T1-T3 (T1: baseline examination; T2: after 3 months; T3: after 6 months).

—

Countries

Germany

Contacts

Public ContactElisabeth Jentschke

Universitätsklinikum Würzburg, Comprehensive Cancer Center Mainfranken

Jentschke_E@ukw.de+4993120128883

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026